NGD-4715

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
NGD-4715
NGD-4715.svg
Identifiers
CAS Number
Chemical and physical data
FormulaC25H30F3N3O3
Molar mass477.528 g·mol−1
3D model (JSmol)

NGD-4715 is a drug developed by Neurogen, which acts as a selective, non-peptide antagonist at the melanin concentrating hormone receptor MCH1.[1] In animal models it has anxiolytic, antidepressant, and anorectic effects,[2] and it has successfully passed Phase I clinical trials in humans.[3]

Neurogen was acquired by Ligand Pharmaceuticals in August, 2009, and NGD-4715 was not listed among its key assets.[4] All four laboratories were closed and sold, and no employees were retained.[5]

The structure of NGD-4715 has been confused. For example, as 1-(5-bromo-6-methoxypyridin-2-yl)-4-(3,4-dimethoxybenzyl)piperazine.

References[edit]

  1. ^ Tarrant, J.; Hodgetts, K.J.; Chenard, B.L.; Krause, J.E.; Doller, D. (2017). "The Discovery of the MCH-1 Receptor Antagonist NGD-4715 for the Potential Treatment of Obesity". Comprehensive Medicinal Chemistry III. pp. 488–515. doi:10.1016/B978-0-12-409547-2.13785-0. ISBN 9780128032015.
  2. ^ Chaki S, Kanuma K. (2007). "Neuropeptide receptors: Novel therapeutic targets for depression and anxiety disorders". Drugs of the Future. 32 (9): 809. doi:10.1358/dof.2007.032.09.1131450.
  3. ^ Neurogen Announces Results of First-in-Human Trial for New Approach to Treating Obesity. Business Wire. May 2 2007
  4. ^ Neurogen acquired by Ligand Pharmaceuticals. Business Wire. August 24, 2009.
  5. ^ Neurogen to sell Real Estate for $3.5m. Chicago Tribune. Nov 10, 2009